Cargando…

Biologics and biosimilars: what, why and how?

Detalles Bibliográficos
Autores principales:	Chan, Juliana CN, Chan, Anthony TC
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	ESMO Open 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519784/ http://dx.doi.org/10.1136/esmoopen-2017-000180

Ejemplares similares

Why are biosimilars much more complex than generics?
por: Pagani, Eduardo
Publicado: (2019)

Integrated multimorbidity management in primary care: why, what, how, and how to?
por: Sturmberg, Joachim P., et al.
Publicado: (2016)

Social Determinants of Health: What, How, Why, and Now
por: Metzler, Marilyn
Publicado: (2007)

The ‘What, Why, Where and How’ of Delivering a Drug
por: Mukherjee, Kusumika
Publicado: (2020)

Pharmacovigilance of biosimilars - Why is it different from generics and innovator biologics?
por: Gupta, Ranjan
Publicado: (2020)

Pharmacovigilance of biosimilars – Why is it different from generics and innovator biologics?
por: Oza, B, et al.
Publicado: (2019)

Scientific Paper Writing for Pediatric Surgeons: Why, What, and How?
por: Chandrasekharam, V. V. S.
Publicado: (2020)

Emerging Insights into European Markets of Biologics, Including Biosimilars
por: Simoens, Steven, et al.
Publicado: (2022)

Biosimilars
por: Martin, Miguel
Publicado: (2018)

Evolution of Clinical Practice Guidelines for Psychiatric Disorders; Why, What And How?
por: Sathyanarayana Rao, T.S., et al.
Publicado: (2004)

From Biologics to Biosimilars and Biobetters – Democratization of High-end Therapeutics
por: Honavar, Santosh G
Publicado: (2021)

How Similar Are Biosimilars? What Do Clinicians Need to Know About Biosimilar and Follow-On Insulins?
por: Triplitt, Curtis, et al.
Publicado: (2017)

Visual abstract for Abdominal Radiology: what it is, why we need it and how to make it
por: Brook, Olga R., et al.
Publicado: (2021)

Navigating the who, where, what, when, how and why of trauma exposure and response
por: Vallières, Frédérique, et al.
Publicado: (2021)

Procedural fairness in health financing for universal health coverage: why, what and how
por: Gopinathan, Unni, et al.
Publicado: (2023)

Editorial Review for: Why Is There Low Utilization of Biosimilars in Inflammatory Bowel Disease Patients by Gastroenterology Advanced Practice Providers?
por: Hanson, Karen
Publicado: (2021)

Economic evaluation of biosimilars for reimbursement purposes – what, when, how?
por: Moorkens, Evelien, et al.
Publicado: (2020)

Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?
por: Toussirot, Eric, et al.
Publicado: (2017)

Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
por: Mysler, Eduardo, et al.
Publicado: (2021)

What can we learn from the recent blood glucose lowering megatrials?
por: Chan, Juliana CN
Publicado: (2011)

Biosimilar insulin concepts
por: Bloomgarden, Zachary T.
Publicado: (2022)

What do oncologists need to know about biosimilar products?
por: Leung, Linda K. S., et al.
Publicado: (2016)

The why, what, and how of publishing a manuscript: A blend of art and science
por: Cortina, Maria S
Publicado: (2023)

The paradox of why and how in urology!
por: Mandhani, Anil
Publicado: (2022)

Biologics and Biosimilars in Psoriasis
por: Ahmed, Sk Shahriar, et al.
Publicado: (2023)

Data citation: what, when, why?
por: Lemberger, Thomas
Publicado: (2018)

The Development Pathway for Biosimilar Biotherapeutics
por: Zarbin, Marco
Publicado: (2020)

Here to Stay: Biosimilars in Hematology
por: Gribben, John, et al.
Publicado: (2019)

Why publish in Biology Letters?
por: Beerling, David
Publicado: (2022)

Calcium Supplementation: Why, Which, and How?
por: Garg, M. K., et al.
Publicado: (2019)

Innovation in plastic surgery–why and how?
por: Hong, Joon Pio
Publicado: (2021)

What are Altmetrics and why would anyone be interested?
por: Watson, Roger
Publicado: (2016)

Why Violence Against Doctors? What to Do?
por: Joseph, Bobby, et al.
Publicado: (2023)

Biosimilars as a strategy to improve sustainability
por: Bria, Emilio, et al.
Publicado: (2017)

Therapeutic Monoclonal Antibodies and Emergence of Their Biosimilars
por: Jeddi-Tehrani, Mahmood
Publicado: (2018)

Biosimilars: Promises Made. Promises Kept?
por: Martinez-Cabriales, Sylvia A., et al.
Publicado: (2021)

There Is No Substitute for Effective Education About Biosimilars
por: Maltz, Ross M, et al.
Publicado: (2021)

Teaching professionalism – Why, What and How
por: Cruess, S.R., et al.
Publicado: (2012)

Flavour Physics: What, Why and How
por: Wyler, D
Publicado: (2002)

Pediatric eye screening – Why, when, and how
por: Honavar, Santosh G
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2g43cfsj5i4vvr4co4is9v1o3n